HC Wainwright Brokers Decrease Earnings Estimates for ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report issued on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of $0.16 for the year, down from their prior forecast of $6.05. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.

A number of other equities analysts have also weighed in on ESPR. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $7.00 price target on shares of Esperion Therapeutics in a research note on Thursday, January 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $7.25.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR opened at $1.95 on Monday. The firm has a 50-day simple moving average of $2.44 and a two-hundred day simple moving average of $2.16. The firm has a market cap of $384.23 million, a P/E ratio of -3.05 and a beta of 1.03. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $51.63 million during the quarter, compared to analysts’ expectations of $55.44 million. During the same period in the previous year, the company posted ($0.37) earnings per share.

Institutional Trading of Esperion Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ESPR. Wasatch Advisors LP boosted its stake in shares of Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after acquiring an additional 6,483,070 shares during the period. Geode Capital Management LLC grew its holdings in Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares in the last quarter. Marshall Wace LLP raised its position in shares of Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after buying an additional 2,087,635 shares during the last quarter. State Street Corp lifted its holdings in shares of Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after buying an additional 99,802 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Esperion Therapeutics by 1.0% during the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock worth $3,414,000 after acquiring an additional 19,588 shares during the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.